Evidence map›Paper›PMID 39015687›Full record

ArticleIranian journal of otorhinolaryngology2024

Epidemiological Study of Head and Neck Sarcomas.

Alireza Assadi, Nezamoddin Berjis, Narges Motamedi, Afrooz Eshaghian

Abstract read
In one paragraph

Article in Iranian journal of otorhinolaryngology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alireza AssadiDepartment of Otorhinolaryngology, school of Medicine, Kashani University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Nezamoddin BerjisDepartment of Otorhinolaryngology, school of Medicine, Kashani University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Narges MotamediDepartment of Community and Family Medicine, school of Medicine, Social Determinants of Health Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Afrooz EshaghianDepartment of Otorhinolaryngology, school of Medicine, Kashani University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Head and neck sarcomas are uncommon tumors that account for less than 1% of head and neck malignancies and fewer than 5% of all sarcomas. This study aims to assess the head and neck sarcomas pattern in Isfahan, Iran, compare its results with previous findings, and investigate treatment methods and the recurrence and survival rate. Materials and Methods: This study was done on 160 patients diagnosed with head and neck sarcomas between 2001 and 2020 in four medical centers in Isfahan, Iran. The patients with head and neck sarcoma confirmed by biopsy were included. Patient information included sex, age at diagnosis, and full characteristics of the mass. Disease recurrence and 2-year and 5-year overall survival (OS) were investigated by phone. Results: Among 160 patients, 94 (58.8%) were male. The mean age was 36.9 ± 23.2 years. The neck was the most reported location for sarcomas (N=34, 21.3%). Undifferentiated pleomorphic sarcoma was the most frequent histopathologic pattern (N=48, 30.0%). The brain and lungs were the most common destinations for metastasis. "Surgery and adjuvant therapy together" was the most common type of treatment (N=108, 68.8%). The 2-year and 5-year recurrence rates were N=100, 62.5%, and N=110, 68.8%, respectively. The 2-year and 5-year OS was N=103, 64.4%, and N=58, 36.6%, respectively. Eighty-nine patients have had metastasis (55.6%). Conclusions: Both 2-year and 5-year recurrence rates and OS were significantly correlated with metastasis. The OS within two years and five years were significantly higher in those treated only by "Surgery".

Indexed as

EpidemiologyHead and NeckSarcoma

Identifiers

PMID39015687
PMCPMC11247447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.